H.C. Wainwright raises Vir Biotechnology price target to $22
H.C. Wainwright raised its price target for Vir Biotechnology (VIR) to $22 from $20, maintaining a Buy rating. The stock is up over 90% year-to-date. The firm increased its success probability for VIR-5500 in prostate cancer to 40%. Vir reported Q2 2026 net income of $80.1M, driven by an Astellas collaboration payment. Raymond James reiterated a Strong Buy rating with a $19 target.
How this was made
The 30-second read
Why it matters
The upgrade reflects confidence in VIR's pipeline and cash position, likely prompting buying interest.
Market read
Vir's price target raise may drive short-term upside, with broader biotech sentiment benefit.
What to watch
Potential competition in the hepatitis D space could limit market share.
Background
Analyst price target updates are a common catalyst for short-term stock moves in biotech.
Ticker impact
H.C. Wainwright raised Vir Biotechnology's price target to $22, indicating increased confidence in its oncology pipeline.
likely upward pressure as investors price in the higher target
Analyst upgrade with a 91% price target increase signals fresh positive catalyst.
Market effects
Positive signal for biotech sector, especially companies with oncology pipelines.
US biotech investors may see increased buying interest.
Limited to investors tracking US-listed biotech stocks.
Counterpoint
Target raise may be premature if upcoming trial data disappoints.
Key entities
- companyVir Biotechnology
US-listed biotech developing oncology and hepatitis D therapies.
- analystH.C. Wainwright
Equity research firm that raised the price target.
